Formación de creadores de empresa

Publicaciones Icesi No. 28 – Julio/Septiembre 1988. Formación de creadores de empresa de Roberto Gaitán Cabezas y Jorge Casa Reye

Estructura y función de un ecosistema de manglar a lo largo de una trayectoria de restauración en diferentes niveles de perturbación

IP 2105-13-080-97Incluye anexos.por Jesus Garay Tinoco ... [et al.]. -- Santa Marta : Invemar,2004. -- 232 p. : il., fotografias ; 33 cm. --;(Publicaciones especiales ; no. 11). -- ISBN 9589734928.;LIBRO(S): Los manglares de la ecorregion Cienaga Grande deSantaMarta : pasado, presente y futuro / editad

No. 28 - Julio/Septiembre 1988 / PUBLICACIONES ICESI: Memorias Segundo Congreso Latinoamericano sobre Espiritu Empresarial

Publicaciones Icesi No. 28 – Julio/Septiembre 1988. Memorias Segundo Congreso Latinoamericano sobre Espíritu EmpresarialContenido: Intervención del doctor Federico Renjifo Vélez, viceministro de Desarrollo Económico -- Discurso de bienvenida a los participantes en el II Congreso Latinoamericano sobre Espíritu Empresarial -- Discurso de inauguración del II Congreso Latinoamericano sobre Espíritu Empresarial – La Asociación de Empresarios Universitarios – Los Programas de Junior Achievement en los Estados Unidos – La experiencia de Birla Institute of Technology en las actividad de desarrollo empresarial – Testimonio empresarial – La experiencia empresarial de Grajales Hermanos – Características de los empresarios de Cali y análisis comparativo con los empresarios de Cali – Perfil del empresario de la Universidad Eafit a nivel Nacional – La pequeña empresa como base de desarrollo económico social en Latinoamérica – La pequeña empresa mexicana – La Universidad Autónoma de Occidente y su Departamento de Gestión Empresarial -- Factores asociado al éxito y principales dificultades de profesionales empresarios de Cali – La formación del ingenierio-empresarial – El modelo de enseñanza aprendizaje en Unitec y la formación de empresarios – El espíritu emprendedor – Proyecto para la creación de un Centro de Formación de Empresas – Plan de negocio para una nueva empresa – Formación de creadores de empresa – Proyecto de desarrollo empresarial y tecnológico – Perfil de la mujer empresaria chilena

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable clinical responses in several tumor types. However, concerns about the safety and feasibility of PD-1/PD-L1 blockade in HIV-1-infected individuals have led to the exclusion of these patients from clinical trials on cancer immunotherapies. To evaluate the feasibility and safety of durvalumab treatment in patients with advanced cancer and virologically controlled HIV-1 infection. The DURVAST study was a nonrandomized, open-label, phase 2 clinical trial in patients with any solid tumor type in which anti-PD-1 or anti-PD-L1 antibodies have approved indications or for which there are data of antitumoral activity with no other available curative therapy. All patients had basal undetectable plasma viremia while undergoing combination antiretroviral therapy. Treatment consisted of intravenous infusion of durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects. Adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 20 HIV-1-infected patients with advanced cancer were enrolled; 16 (80%) were male, the median (range) age was 54 (30-73) years, and 12 (60%) had progressed with previous cancer treatment lines. A median (range) of 4 (1-16) cycles of durvalumab were administered. Drug-related adverse events were observed in 50% of patients, and all were grade 1 and 2 (mainly diarrhea, asthenia, and arthromyalgia). Four of 16 response-evaluable patients (25%) had a partial response. Five patients (31%) had stable disease, including 4 with durable stable disease (disease control rate of 50%). CD4+ and CD8+ T-cell counts and plasma HIV-1 viremia remained stable throughout the study. Durvalumab treatment was feasible and safe in HIV-1-infected patients with cancer receiving combination antiretroviral therapy. HIV-1-infected patients on suppressive antiretroviral therapy with advanced cancer should have access to cancer immunotherapy treatments. ClinicalTrials.gov Identifier: NCT03094286

The Phase 2 DURVAST Study

[Importance] Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable clinical responses in several tumor types. However, concerns about the safety and feasibility of PD-1/PD-L1 blockade in HIV-1–infected individuals have led to the exclusion of these patients from clinical trials on cancer immunotherapies.[Objective] To evaluate the feasibility and safety of durvalumab treatment in patients with advanced cancer and virologically controlled HIV-1 infection.[Design, Setting, and Participants] The DURVAST study was a nonrandomized, open-label, phase 2 clinical trial in patients with any solid tumor type in which anti–PD-1 or anti–PD-L1 antibodies have approved indications or for which there are data of antitumoral activity with no other available curative therapy. All patients had basal undetectable plasma viremia while undergoing combination antiretroviral therapy.[Interventions] Treatment consisted of intravenous infusion of durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects.[Main Outcomes and Measures] Adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1.[Results] A total of 20 HIV-1–infected patients with advanced cancer were enrolled; 16 (80%) were male, the median (range) age was 54 (30-73) years, and 12 (60%) had progressed with previous cancer treatment lines. A median (range) of 4 (1-16) cycles of durvalumab were administered. Drug-related adverse events were observed in 50% of patients, and all were grade 1 and 2 (mainly diarrhea, asthenia, and arthromyalgia). Four of 16 response-evaluable patients (25%) had a partial response. Five patients (31%) had stable disease, including 4 with durable stable disease (disease control rate of 50%). CD4+ and CD8+ T-cell counts and plasma HIV-1 viremia remained stable throughout the study.[Conclusions and Relevance] Durvalumab treatment was feasible and safe in HIV-1–infected patients with cancer receiving combination antiretroviral therapy. HIV-1–infected patients on suppressive antiretroviral therapy with advanced cancer should have access to cancer immunotherapy treatments.[Trial Registration] ClinicalTrials.gov Identifier: NCT03094286.This study was sponsored by the Spanish Lung Cancer Group (SLCG) and supported by the AstraZeneca Group. A Marie Skłodowska-Curie Innovative Training Networks European Grant (ELBA No. 765492), the Spanish Association Against Cancer (AECC) (grant No.PROYE18012ROSE), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) supported in part the associated translational study